Sandoz: UBS downgrades stock
(CercleFinance.com) - UBS downgrades its recommendation on Sandoz shares from 'buy' to 'neutral', despite raising its target price on the generic and biosimilar drugmaker's stock from 39.
5 CHF to 44 CHF, suggesting a 'pause for breath'.
The broker explains that it is downgrading its rating after a period of strong outperformance, seeing no further upside potential in relation to consensus expectations on biosimilars, and preferring Galderma among Swiss mid-caps.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
5 CHF to 44 CHF, suggesting a 'pause for breath'.
The broker explains that it is downgrading its rating after a period of strong outperformance, seeing no further upside potential in relation to consensus expectations on biosimilars, and preferring Galderma among Swiss mid-caps.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.